Search

You searched for "cysts"

559 results found

Bladder carcinoma MRI

1 September 2018 | | URO - Urologic Oncology, URO - Uroradiology
Bladder malignancy is one of the commonest malignancies of the renal tract, accounting for approximately 6% of male malignancy and 2% of female malignancy. The incidence increases with patient age with 70% of patients being over the age of 65...

Demanding cases or nightmares in uro-oncology? May/Jun 2022

3 May 2022 | | URO - Urologic Oncology
Delayed diagnosis of testicular cancer Testicular cancer is considered rare in the general population but is the most common cancer affecting males between 24 and 49 years. The diagnosis of testicular cancer depends on physical examination, ultrasound findings and tumour...

So you want to be a urologist?

1 March 2017 | | URO - Core Urology
Urology is a varied, innovative and friendly speciality and it is easy to see why so many people are attracted to it. The article below is designed to help all doctors wishing to apply for an ST3 post get the...

Robotic Urology Fellowship at UCLH

1 May 2016 | | URO - Core Urology
In November 2014, approaching my final year of training (ST7) in the West of Scotland (WoS) and just recently armed with my FRCS (Urol), I was at a crossroad in my clinical career. I was keen to pursue a consultant...

The Lister Royal College of Surgeons of England / BAUS Accredited Robotic Urological Fellowship Programme

1 September 2015 | | URO - Core Urology
Robotic fellowship training in the UK – overview Robotic surgery has increased in popularity since its introduction in 2003. Its validation in a growing number of operative procedures has increased its acceptance nationwide and its usage is becoming widespread. Initial...

Management of stage 1 non-seminomatous germ cell tumours

1 November 2014 | | URO - Urologic Oncology
Testicular cancer (TC) is the most successfully treated solid tumour, achieving a cure rate of 90-95% [1-3]. Testicular cancer is relatively rare with an incidence of 2207 cases in the UK in 2014 [4] and yet is the most common...

Neuroendocrine bladder tumour

5 February 2025 | | URO - Urologic Oncology
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...

BXTAccelyon becomes global distribution partner for new online prostate MRI self-learning tool to enhance prostate cancer diagnosis

6 May 2020 | Contracts & Distributors
BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the...

CESCI Partnership with the Spinal Injuries Association

5 June 2024 | URO - Neurourology, URO - Trauma & Emergency
Cauda Equina Spinal Cord Injury (CESCI) are thrilled to announce their new partnership with the Spinal Injuries Association (SIA). This collaboration represents a significant step forward in their mission to support individuals living with cauda equina syndrome (CES). CESCI is...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

1 May 2017 | | URO - Urologic Oncology
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

Focal therapy for prostate cancer – ready for prime time?

1 November 2016 | | URO - Basic Science Research, URO - Urologic Oncology
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...

Bladder cancer: where are we with intravesical therapies?

1 July 2016 | | URO - Urologic Oncology
In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...